Patrick J. Mahaffy
Net Worth
Last updated:
What is Patrick J. Mahaffy net worth?
The estimated net worth of Mr. Patrick J. Mahaffy is at least $17,294,971 as of 16 Aug 2019. He owns shares worth $74,971 as insider and has received compensation worth at least $17,220,000 in Clovis Oncology, Inc..
What is the salary of Patrick J. Mahaffy?
Mr. Patrick J. Mahaffy salary is $1,230,000 per year as Co-Founder, Chief Executive Officer, Pres & Executive Director in Clovis Oncology, Inc..
How old is Patrick J. Mahaffy?
Mr. Patrick J. Mahaffy is 62 years old, born in 1963.
What stocks does Patrick J. Mahaffy currently own?
As insider, Mr. Patrick J. Mahaffy owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Clovis Oncology, Inc. (CLVS) | Co-Founder, Chief Executive Officer, Pres & Executive Director | 923,293 | $0.08 | $74,971 |
What does Clovis Oncology, Inc. do?
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Patrick J. Mahaffy insider trading
Clovis Oncology key executives
Clovis Oncology, Inc. executives and other stock owners filed with the SEC:
- Dr. Gillian C. Ivers-Read (71) Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations
- Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM (57) Executive Vice President of Clinical Devel. & Pharmacovigilance and Chief Medical Officer
- Mr. Daniel W. Muehl (61) Executive Vice President & Chief Financial Officer
- Mr. Patrick J. Mahaffy (62) Co-Founder, Chief Executive Officer, Pres & Executive Director
- Mr. Paul Edward Gross (60) Executive Vice President, Gen. Counsel & Sec.